T-lymphotrophic virus
CA 1270756 C · Owner: President And Fellows Of Harvard College · Inventors: Essex, Myron E.; Kanki, Phyllis J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Abstract of the Disclosure A substantially pure polypeptide having at least one antigenic determinant that is substantially identical to an antigenic determinant of a protein from a cell line infected with simian T-lymphotrophic virus-III or human T-lymphotrophic virus-IV (HTLV-IV) the protein being selected from: a) a glycoprotein having a molecular weight (m.w.) of about 160,000 daltons; a glycoprotein having a m.w. of about 120,000 daltons; a gag protein having a m.w. of about 55,000 daltons; a gag protein having a m.w. of about 24,000 daltons; and a glycoprotein having a m.w. of about 32,000 daltons. also disclosed are various methods of immunoassay using that peptide or antibodies …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Granted June 26, 1990. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended June 26, 2007.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.